Meredith Pelster

1.3k total citations · 2 hit papers
29 papers, 832 citations indexed

About

Meredith Pelster is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Meredith Pelster has authored 29 papers receiving a total of 832 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Oncology, 9 papers in Pulmonary and Respiratory Medicine and 8 papers in Molecular Biology. Recurrent topics in Meredith Pelster's work include Colorectal Cancer Treatments and Studies (10 papers), Cancer Immunotherapy and Biomarkers (8 papers) and Advanced Breast Cancer Therapies (4 papers). Meredith Pelster is often cited by papers focused on Colorectal Cancer Treatments and Studies (10 papers), Cancer Immunotherapy and Biomarkers (8 papers) and Advanced Breast Cancer Therapies (4 papers). Meredith Pelster collaborates with scholars based in United States, Australia and United Kingdom. Meredith Pelster's co-authors include Rodabe N. Amaria, Alexander I. Spira, Minal Barve, Rona Yaeger, Tanios Bekaii‐Saab, Hirak Der‐Torossian, Karen Velastegui, Ticiana Leal, James G. Christensen and Cloud P. Paweletz and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Meredith Pelster

27 papers receiving 823 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Adagrasib with or without Cetuximab in Colorectal Cancer with Mutated KRAS G12C

2022 269 citations Rona Yaeger, Meredith Pelster et al. profile →
Adagrasib in Advanced Solid Tumors Harboring aKRAS^G12CMutation

2023 139 citations Tanios Bekaii‐Saab, Rona Yaeger et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Meredith Pelster United States	9	556	311	190	157	154	29	832
Eleonora Sementino United States	12	278 0.5×	421 1.4×	93 0.5×	169 1.1×	90 0.6×	21	1.2k
R.J. Salmon France	11	459 0.8×	185 0.6×	75 0.4×	138 0.9×	339 2.2×	22	789
Brigida Anna Maiorano Italy	15	343 0.6×	125 0.4×	145 0.8×	67 0.4×	92 0.6×	58	531
Teofila Seremet Belgium	15	630 1.1×	351 1.1×	387 2.0×	236 1.5×	22 0.1×	35	928
Hojabr Kakavand Australia	15	1.1k 2.0×	501 1.6×	583 3.1×	162 1.0×	78 0.5×	20	1.4k
Ingrid Lebigot France	8	286 0.5×	248 0.8×	44 0.2×	191 1.2×	77 0.5×	8	543
Michelle R. Pereira Australia	13	415 0.7×	322 1.0×	102 0.5×	510 3.2×	59 0.4×	19	735
Maria B. Karpova Switzerland	15	379 0.7×	596 1.9×	145 0.8×	90 0.6×	15 0.1×	31	951
H. David Inzunza United States	8	798 1.4×	225 0.7×	483 2.5×	90 0.6×	13 0.1×	12	1.0k
Susan Jewell United States	10	563 1.0×	424 1.4×	80 0.4×	245 1.6×	36 0.2×	15	779

Countries citing papers authored by Meredith Pelster

Since Specialization

Citations

This map shows the geographic impact of Meredith Pelster's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Meredith Pelster with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Meredith Pelster more than expected).

Fields of papers citing papers by Meredith Pelster

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Meredith Pelster. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Meredith Pelster. The network helps show where Meredith Pelster may publish in the future.

Co-authorship network of co-authors of Meredith Pelster

This figure shows the co-authorship network connecting the top 25 collaborators of Meredith Pelster. A scholar is included among the top collaborators of Meredith Pelster based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Meredith Pelster. Meredith Pelster is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Eads, Jennifer R., Maria Pia Morelli, Daniel J. Olson, et al.. (2025). A phase 1/2 study to evaluate CHM-2101, an autologous cadherin 17 (CDH17) chimeric antigen receptor (CAR) T cell therapy for the treatment of relapsed or refractory gastrointestinal cancers.. Journal of Clinical Oncology. 43(4_suppl).

Li, Daneng, Kun‐Ming Rau, Ming‐Lung Yu, et al.. (2025). Results from a phase 2 study of triplet blockade of the IL-27, PD-(L)1, and VEGF pathways with casdozokitug (casdozo, CHS-388) in combination with atezolizumab and bevacizumab in patients with unresectable, locally advanced or metastatic hepatocellular carcinoma (uHCC).. Journal of Clinical Oncology. 43(4_suppl). 605–605. 1 indexed citations

Hecht, J. Randolph, Alexander I. Spira, Anthony V. Nguyen, et al.. (2025). A randomized phase 2 study of an individualized neoantigen-targeting immunotherapy in patients with newly diagnosed metastatic microsatellite stable colorectal cancer (MSS-CRC).. Journal of Clinical Oncology. 43(4_suppl). 3 indexed citations

Jaminet, Shou-Ching, et al.. (2025). AGX101: A TM4SF1-directed tubulin inhibitor conjugate in ongoing first-in-human trial including GI cancers.. Journal of Clinical Oncology. 43(4_suppl). 829–829. 1 indexed citations

Yaeger, Rona, Nataliya V. Uboha, Samuel J. Klempner, et al.. (2025). Adagrasib (Ada) + cetuximab (Cetux) for KRAS ^G12C -mutated metastatic colorectal cancer (mCRC): Longer follow-up analysis from KRYSTAL-1.. Journal of Clinical Oncology. 43(4_suppl). 131–131. 1 indexed citations

Patnaik, Amita, Meredith Pelster, David S. Hong, et al.. (2024). A phase 1 trial evaluating the safety, tolerability, PK, and preliminary efficacy of QTX3034, an oral G12D-preferring multi-KRAS inhibitor, in patients with solid tumors with KRAS^G12D mutation.. Journal of Clinical Oncology. 42(16_suppl). TPS3172–TPS3172. 6 indexed citations

Punekar, Salman R., Meredith Pelster, Carlos Becerra, et al.. (2024). An open-label, phase 1, multicenter study to evaluate the safety and preliminary anti-tumor activity of NT-112 in human leukocyte antigen-C*08:02–positive adult patients with unresectable, advanced, and/or metastatic solid tumors that are positive for the KRAS G12D mutation.. Journal of Clinical Oncology. 42(16_suppl). TPS2677–TPS2677. 3 indexed citations

Patnaik, Amita, Nilofer S. Azad, Mitesh J. Borad, et al.. (2024). An open-label phase 1 study to investigate SGNCEACAM5C/SAR445953 in adults with advanced solid tumors (SGNCEA5C-001).. Journal of Clinical Oncology. 42(16_suppl). TPS3160–TPS3160. 1 indexed citations

Bekaii‐Saab, Tanios, Rona Yaeger, Alexander I. Spira, et al.. (2023). Adagrasib in Advanced Solid Tumors Harboring aKRAS^G12CMutation. Journal of Clinical Oncology. 41(25). 4097–4106. 139 indexed citations breakdown →

10.

Oberstein, Paul E., et al.. (2023). ONCX-NAV-G201: A phase 2 basket study of navicixizumab monotherapy or in combination with chemotherapy in patients with select advanced solid tumors—Colorectal Cancer Cohort (trial in progress).. Journal of Clinical Oncology. 41(4_suppl). TPS263–TPS263. 1 indexed citations

11.

Naing, Aung, Hirva Mamdani, Minal Barve, et al.. (2023). 652 NT-I7 (efineptakin alfa), a long-acting IL-7, in combination with pembrolizumab improves T cell fitness in heavily pretreated subjects with gastrointestinal tumors. SHILAP Revista de lepidopterología. A743–A743. 1 indexed citations

12.

Luckett, Daniel J., Marilyn Holt, Suzanne F. Jones, et al.. (2023). Clinical and molecular presentation of KRAS G12D-mutated pancreatic ductal adenocarcinoma in real-world settings.. Journal of Clinical Oncology. 41(4_suppl). 738–738. 1 indexed citations

13.

Sharma, Sunil, Alexander Starodub, Nong Xu, et al.. (2023). Preliminary results of a phase 1/2, first-in-human, open-label, dose escalation study of ZL-1211 (anti-Claudin 18.2 mAb) in patients with unresectable or metastatic solid tumors.. Journal of Clinical Oncology. 41(16_suppl). 2537–2537. 6 indexed citations

14.

Naing, Aung, Meredith Pelster, Alexander I. Spira, et al.. (2022). 747 A phase 1 trial of IO-202, an antagonist antibody targeting myeloid checkpoint LILRB4 (ILT3), as monotherapy and in combination with pembrolizumab in adult patients with advanced relapsed or refractory solid tumors. Regular and Young Investigator Award Abstracts. A780–A780. 4 indexed citations

15.

Pelster, Meredith, et al.. (2022). A multicenter, open-label, phase 1a/b study of HC-7366, a modulator of integrated stress response (ISR) kinase GCN2 in subjects with advanced solid tumors.. Journal of Clinical Oncology. 40(16_suppl). TPS3179–TPS3179. 1 indexed citations

16.

Pelster, Meredith & Rodabe N. Amaria. (2020). Neoadjuvant Immunotherapy for Locally Advanced Melanoma. Current Treatment Options in Oncology. 21(2). 10–10. 12 indexed citations

17.

Rodriguez, J.M. Piulats, Shreyaskumar Patel, Enrique Espinosa, et al.. (2020). 1143P Nivolumab and ipilimumab (N+I) is active in patients (pts) with metastatic uveal melanoma (mUM) with extra-hepatic only involvement: Pooled analysis from 2 phase II trials. Annals of Oncology. 31. S764–S764. 3 indexed citations

18.

Pelster, Meredith, Stephen K. Gruschkus, Roland L. Bassett, et al.. (2020). Nivolumab and Ipilimumab in Metastatic Uveal Melanoma: Results From a Single-Arm Phase II Study. Journal of Clinical Oncology. 39(6). 599–607. 185 indexed citations

19.

Pelster, Meredith & Rodabe N. Amaria. (2019). Combined targeted therapy and immunotherapy in melanoma: a review of the impact on the tumor microenvironment and outcomes of early clinical trials. Therapeutic Advances in Medical Oncology. 11. 3862445866–3862445866. 111 indexed citations

20.

Pelster, Meredith, Stephen K. Gruschkus, Roland L. Bassett, et al.. (2019). Phase II study of ipilimumab and nivolumab (ipi/nivo) in metastatic uveal melanoma (UM).. Journal of Clinical Oncology. 37(15_suppl). 9522–9522. 19 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact